Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREK: Spravato vs Racemic Ketamine in Treatment-Resistant Depression
NCT06278779Phase 4Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of esketamine, ketamine in treatment-resistant depression (TRD), sponsored by The George Institute for Global Health. Started Jun 2024; status: recruiting.
02
Drugs
esketamineketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06278779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278779.